APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sepsis and Septic Shock Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Sepsis and Septic Shock Treatment Market Analysis and Forecast 2026-2032

2 January 2026204 pages

Choose your research edition.

Industry ResearchSepsis and Septic Shock Treatment Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Sepsis and Septic Shock Treatment Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Sepsis and Septic Shock Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sepsis and Septic Shock Treatment Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Sepsis and Septic Shock Treatment Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Sepsis and Septic Shock Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Sepsis and Septic Shock Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Sepsis and Septic Shock Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Sepsis and Septic Shock Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Sepsis and Septic Shock Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Sepsis and Septic Shock Treatment include TEVA, Johnson & Johnson, Novartis, Pfizer, GlaxoSmithKline, Bayer, AbbVie, Viatris and Shanghai Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Sepsis and Septic Shock Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Sepsis and Septic Shock Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Sepsis and Septic Shock Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Sepsis and Septic Shock Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Sepsis and Septic Shock Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Sepsis and Septic Shock Treatment revenue, projected growth trends, production technology, application and end-user industry.

Sepsis and Septic Shock Treatment Segment by Company

TEVA

Johnson & Johnson

Novartis

Pfizer

GlaxoSmithKline

Bayer

AbbVie

Viatris

Shanghai Pharmaceuticals

NCPC

Merck & Co

INOTREM

Endacea

AtoxBio

Asahi Kasei

Adrenomed

Sepsis and Septic Shock Treatment Segment by Type

Macrolides

Pencillin

Cephalosporin

Others

Sepsis and Septic Shock Treatment Segment by Application

Sepsis

Septic Shock

Sepsis and Septic Shock Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sepsis and Septic Shock Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sepsis and Septic Shock Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sepsis and Septic Shock Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Sepsis and Septic Shock Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Sepsis and Septic Shock Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sepsis and Septic Shock Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Sepsis and Septic Shock Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Macrolides Major Player Table 3. Pencillin Major Player Table 4. Cephalosporin Major Player Table 5. Others Major Player Table 6. Global Sepsis and Septic Shock Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Sepsis Major Player Table 8. Septic Shock Major Player Table 9. Sepsis and Septic Shock Treatment Industry Trends Table 10. Sepsis and Septic Shock Treatment Industry Drivers Table 11. Sepsis and Septic Shock Treatment Industry Opportunities and Challenges Table 12. Sepsis and Septic Shock Treatment Industry Restraints Table 13. Global Sepsis and Septic Shock Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Sepsis and Septic Shock Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Sepsis and Septic Shock Treatment Market Share by Region (2021-2026) Table 16. Global Sepsis and Septic Shock Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Sepsis and Septic Shock Treatment Market Share by Region (2027-2032) Table 18. Global Sepsis and Septic Shock Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Sepsis and Septic Shock Treatment Revenue Market Share by Players (2021-2026) Table 20. Global Sepsis and Septic Shock Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Sepsis and Septic Shock Treatment Key Players Headquarters & Area Served Table 22. Global Sepsis and Septic Shock Treatment Players, Product Type & Application Table 23. Global Sepsis and Septic Shock Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Sepsis and Septic Shock Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Sepsis and Septic Shock Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Sepsis and Septic Shock Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Sepsis and Septic Shock Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Sepsis and Septic Shock Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Sepsis and Septic Shock Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Sepsis and Septic Shock Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Sepsis and Septic Shock Treatment Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Sepsis and Septic Shock Treatment Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Sepsis and Septic Shock Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Sepsis and Septic Shock Treatment Revenue Market Share by Application (2027-2032) Table 36. TEVA Company Information Table 37. TEVA Business Overview Table 38. TEVA Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. TEVA Sepsis and Septic Shock Treatment Product Portfolio Table 40. TEVA Recent Development Table 41. Johnson & Johnson Company Information Table 42. Johnson & Johnson Business Overview Table 43. Johnson & Johnson Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Johnson & Johnson Sepsis and Septic Shock Treatment Product Portfolio Table 45. Johnson & Johnson Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis Sepsis and Septic Shock Treatment Product Portfolio Table 50. Novartis Recent Development Table 51. Pfizer Company Information Table 52. Pfizer Business Overview Table 53. Pfizer Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Pfizer Sepsis and Septic Shock Treatment Product Portfolio Table 55. Pfizer Recent Development Table 56. GlaxoSmithKline Company Information Table 57. GlaxoSmithKline Business Overview Table 58. GlaxoSmithKline Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. GlaxoSmithKline Sepsis and Septic Shock Treatment Product Portfolio Table 60. GlaxoSmithKline Recent Development Table 61. Bayer Company Information Table 62. Bayer Business Overview Table 63. Bayer Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Bayer Sepsis and Septic Shock Treatment Product Portfolio Table 65. Bayer Recent Development Table 66. AbbVie Company Information Table 67. AbbVie Business Overview Table 68. AbbVie Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. AbbVie Sepsis and Septic Shock Treatment Product Portfolio Table 70. AbbVie Recent Development Table 71. Viatris Company Information Table 72. Viatris Business Overview Table 73. Viatris Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Viatris Sepsis and Septic Shock Treatment Product Portfolio Table 75. Viatris Recent Development Table 76. Shanghai Pharmaceuticals Company Information Table 77. Shanghai Pharmaceuticals Business Overview Table 78. Shanghai Pharmaceuticals Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Shanghai Pharmaceuticals Sepsis and Septic Shock Treatment Product Portfolio Table 80. Shanghai Pharmaceuticals Recent Development Table 81. NCPC Company Information Table 82. NCPC Business Overview Table 83. NCPC Sepsis and Septic Shock Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. NCPC Sepsis and Septic Shock Treatment Product Portfolio Table 85. NCPC Recent Development Table 86. Merck & Co Company Information Table 87. Merck & Co Business Overview Table 88. Merck & Co Sepsis and Septic Shock Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Merck & Co Sepsis and Septic Shock Treatment Product Portfolio Table 90. Merck & Co Recent Development Table 91. INOTREM Company Information Table 92. INOTREM Business Overview Table 93. INOTREM Sepsis and Septic Shock Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. INOTREM Sepsis and Septic Shock Treatment Product Portfolio Table 95. INOTREM Recent Development Table 96. Endacea Company Information Table 97. Endacea Business Overview Table 98. Endacea Sepsis and Septic Shock Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Endacea Sepsis and Septic Shock Treatment Product Portfolio Table 100. Endacea Recent Development Table 101. AtoxBio Company Information Table 102. AtoxBio Business Overview Table 103. AtoxBio Sepsis and Septic Shock Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. AtoxBio Sepsis and Septic Shock Treatment Product Portfolio Table 105. AtoxBio Recent Development Table 106. Asahi Kasei Company Information Table 107. Asahi Kasei Business Overview Table 108. Asahi Kasei Sepsis and Septic Shock Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Asahi Kasei Sepsis and Septic Shock Treatment Product Portfolio Table 110. Asahi Kasei Recent Development Table 111. Adrenomed Company Information Table 112. Adrenomed Business Overview Table 113. Adrenomed Sepsis and Septic Shock Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Adrenomed Sepsis and Septic Shock Treatment Product Portfolio Table 115. Adrenomed Recent Development Table 116. North America Sepsis and Septic Shock Treatment Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Sepsis and Septic Shock Treatment Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Sepsis and Septic Shock Treatment Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Sepsis and Septic Shock Treatment Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Sepsis and Septic Shock Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Sepsis and Septic Shock Treatment Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Sepsis and Septic Shock Treatment Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Sepsis and Septic Shock Treatment Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Sepsis and Septic Shock Treatment Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Sepsis and Septic Shock Treatment Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Sepsis and Septic Shock Treatment Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Sepsis and Septic Shock Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Sepsis and Septic Shock Treatment Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Sepsis and Septic Shock Treatment Revenue by Country (US$ Million) & (2027-2032) Table 130. China Sepsis and Septic Shock Treatment Revenue by Type (2021-2026) & (US$ Million) Table 131. China Sepsis and Septic Shock Treatment Revenue by Type (2027-2032) & (US$ Million) Table 132. China Sepsis and Septic Shock Treatment Revenue by Application (2021-2026) & (US$ Million) Table 133. China Sepsis and Septic Shock Treatment Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Sepsis and Septic Shock Treatment Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Sepsis and Septic Shock Treatment Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Sepsis and Septic Shock Treatment Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia Sepsis and Septic Shock Treatment Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Sepsis and Septic Shock Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Sepsis and Septic Shock Treatment Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Sepsis and Septic Shock Treatment Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Sepsis and Septic Shock Treatment Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Sepsis and Septic Shock Treatment Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Sepsis and Septic Shock Treatment Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA Sepsis and Septic Shock Treatment Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA Sepsis and Septic Shock Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Sepsis and Septic Shock Treatment Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Sepsis and Septic Shock Treatment Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Sepsis and Septic Shock Treatment Image Figure 2. Global Sepsis and Septic Shock Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sepsis and Septic Shock Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Macrolides Image Figure 5. Pencillin Image Figure 6. Cephalosporin Image Figure 7. Others Image Figure 8. Global Sepsis and Septic Shock Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Sepsis and Septic Shock Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Sepsis Image Figure 11. Septic Shock Image Figure 12. Global Sepsis and Septic Shock Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global Sepsis and Septic Shock Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Sepsis and Septic Shock Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Sepsis and Septic Shock Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Sepsis and Septic Shock Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Sepsis and Septic Shock Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Sepsis and Septic Shock Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Sepsis and Septic Shock Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Sepsis and Septic Shock Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Sepsis and Septic Shock Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Sepsis and Septic Shock Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032) Figure 25. North America Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032) Figure 26. North America Sepsis and Septic Shock Treatment Revenue Share by Country (2021-2032) Figure 27. United States Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Sepsis and Septic Shock Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032) Figure 32. Europe Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032) Figure 33. Europe Sepsis and Septic Shock Treatment Revenue Share by Country (2021-2032) Figure 34. Germany Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Sepsis and Septic Shock Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032) Figure 44. China Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032) Figure 45. Asia Sepsis and Septic Shock Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032) Figure 47. Asia Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Sepsis and Septic Shock Treatment Revenue Share by Region (2021-2032) Figure 49. Japan Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Sepsis and Septic Shock Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA Sepsis and Septic Shock Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Sepsis and Septic Shock Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Macrolides
  • Pencillin
  • Cephalosporin
  • Others
Applications
  • Sepsis
  • Septic Shock
Companies covered
  • TEVA
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AbbVie
  • Viatris
  • Shanghai Pharmaceuticals
  • NCPC
  • Merck & Co
  • INOTREM
  • Endacea
  • AtoxBio
  • Asahi Kasei
  • Adrenomed

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Sepsis and Septic Shock Treatment Market by Type
  3. 1.2.1 Global Sepsis and Septic Shock Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Macrolides
  5. 1.2.3 Pencillin
  6. 1.2.4 Cephalosporin
  7. 1.2.5 Others
  8. 1.3 Sepsis and Septic Shock Treatment Market by Application
  9. 1.3.1 Global Sepsis and Septic Shock Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Sepsis
  11. 1.3.3 Septic Shock
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Sepsis and Septic Shock Treatment Market Dynamics
  1. 2.1 Sepsis and Septic Shock Treatment Industry Trends
  2. 2.2 Sepsis and Septic Shock Treatment Industry Drivers
  3. 2.3 Sepsis and Septic Shock Treatment Industry Opportunities and Challenges
  4. 2.4 Sepsis and Septic Shock Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Sepsis and Septic Shock Treatment Market Perspective (2021-2032)
  2. 3.2 Global Sepsis and Septic Shock Treatment Growth Trends by Region
  3. 3.2.1 Global Sepsis and Septic Shock Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Sepsis and Septic Shock Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Sepsis and Septic Shock Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Sepsis and Septic Shock Treatment Revenue by Players
  2. 4.1.1 Global Sepsis and Septic Shock Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Sepsis and Septic Shock Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Sepsis and Septic Shock Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Sepsis and Septic Shock Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Sepsis and Septic Shock Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Sepsis and Septic Shock Treatment Players, Product Type & Application
  8. 4.5 Global Sepsis and Septic Shock Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Sepsis and Septic Shock Treatment Market CR5 and HHI
  11. 4.6.3 2025 Sepsis and Septic Shock Treatment Tier 1, Tier 2, and Tier 3
5 Sepsis and Septic Shock Treatment Market Size by Type
  1. 5.1 Global Sepsis and Septic Shock Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Sepsis and Septic Shock Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Sepsis and Septic Shock Treatment Revenue Market Share by Type (2021-2032)
6 Sepsis and Septic Shock Treatment Market Size by Application
  1. 6.1 Global Sepsis and Septic Shock Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Sepsis and Septic Shock Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Sepsis and Septic Shock Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 TEVA
  2. 7.1.1 TEVA Company Information
  3. 7.1.2 TEVA Business Overview
  4. 7.1.3 TEVA Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 TEVA Sepsis and Septic Shock Treatment Product Portfolio
  6. 7.1.5 TEVA Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Sepsis and Septic Shock Treatment Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Sepsis and Septic Shock Treatment Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Sepsis and Septic Shock Treatment Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Sepsis and Septic Shock Treatment Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 Bayer
  32. 7.6.1 Bayer Company Information
  33. 7.6.2 Bayer Business Overview
  34. 7.6.3 Bayer Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bayer Sepsis and Septic Shock Treatment Product Portfolio
  36. 7.6.5 Bayer Recent Developments
  37. 7.7 AbbVie
  38. 7.7.1 AbbVie Company Information
  39. 7.7.2 AbbVie Business Overview
  40. 7.7.3 AbbVie Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AbbVie Sepsis and Septic Shock Treatment Product Portfolio
  42. 7.7.5 AbbVie Recent Developments
  43. 7.8 Viatris
  44. 7.8.1 Viatris Company Information
  45. 7.8.2 Viatris Business Overview
  46. 7.8.3 Viatris Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Viatris Sepsis and Septic Shock Treatment Product Portfolio
  48. 7.8.5 Viatris Recent Developments
  49. 7.9 Shanghai Pharmaceuticals
  50. 7.9.1 Shanghai Pharmaceuticals Company Information
  51. 7.9.2 Shanghai Pharmaceuticals Business Overview
  52. 7.9.3 Shanghai Pharmaceuticals Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Shanghai Pharmaceuticals Sepsis and Septic Shock Treatment Product Portfolio
  54. 7.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 7.10 NCPC
  56. 7.10.1 NCPC Company Information
  57. 7.10.2 NCPC Business Overview
  58. 7.10.3 NCPC Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 NCPC Sepsis and Septic Shock Treatment Product Portfolio
  60. 7.10.5 NCPC Recent Developments
  61. 7.11 Merck & Co
  62. 7.11.1 Merck & Co Company Information
  63. 7.11.2 Merck & Co Business Overview
  64. 7.11.3 Merck & Co Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Merck & Co Sepsis and Septic Shock Treatment Product Portfolio
  66. 7.11.5 Merck & Co Recent Developments
  67. 7.12 INOTREM
  68. 7.12.1 INOTREM Company Information
  69. 7.12.2 INOTREM Business Overview
  70. 7.12.3 INOTREM Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 INOTREM Sepsis and Septic Shock Treatment Product Portfolio
  72. 7.12.5 INOTREM Recent Developments
  73. 7.13 Endacea
  74. 7.13.1 Endacea Company Information
  75. 7.13.2 Endacea Business Overview
  76. 7.13.3 Endacea Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Endacea Sepsis and Septic Shock Treatment Product Portfolio
  78. 7.13.5 Endacea Recent Developments
  79. 7.14 AtoxBio
  80. 7.14.1 AtoxBio Company Information
  81. 7.14.2 AtoxBio Business Overview
  82. 7.14.3 AtoxBio Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  83. 7.14.4 AtoxBio Sepsis and Septic Shock Treatment Product Portfolio
  84. 7.14.5 AtoxBio Recent Developments
  85. 7.15 Asahi Kasei
  86. 7.15.1 Asahi Kasei Company Information
  87. 7.15.2 Asahi Kasei Business Overview
  88. 7.15.3 Asahi Kasei Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Asahi Kasei Sepsis and Septic Shock Treatment Product Portfolio
  90. 7.15.5 Asahi Kasei Recent Developments
  91. 7.16 Adrenomed
  92. 7.16.1 Adrenomed Company Information
  93. 7.16.2 Adrenomed Business Overview
  94. 7.16.3 Adrenomed Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Adrenomed Sepsis and Septic Shock Treatment Product Portfolio
  96. 7.16.5 Adrenomed Recent Developments
8 North America
  1. 8.1 North America Sepsis and Septic Shock Treatment Revenue (2021-2032)
  2. 8.2 North America Sepsis and Septic Shock Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Sepsis and Septic Shock Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Sepsis and Septic Shock Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Sepsis and Septic Shock Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Sepsis and Septic Shock Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Sepsis and Septic Shock Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Sepsis and Septic Shock Treatment Revenue by Country
  11. 8.6.1 North America Sepsis and Septic Shock Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Sepsis and Septic Shock Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Sepsis and Septic Shock Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Sepsis and Septic Shock Treatment Revenue (2021-2032)
  2. 9.2 Europe Sepsis and Septic Shock Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Sepsis and Septic Shock Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Sepsis and Septic Shock Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Sepsis and Septic Shock Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Sepsis and Septic Shock Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Sepsis and Septic Shock Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Sepsis and Septic Shock Treatment Revenue by Country
  11. 9.6.1 Europe Sepsis and Septic Shock Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Sepsis and Septic Shock Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Sepsis and Septic Shock Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Sepsis and Septic Shock Treatment Revenue (2021-2032)
  2. 10.2 China Sepsis and Septic Shock Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Sepsis and Septic Shock Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Sepsis and Septic Shock Treatment Revenue by Type (2027-2032)
  5. 10.3 China Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Sepsis and Septic Shock Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Sepsis and Septic Shock Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Sepsis and Septic Shock Treatment Revenue by Application (2027-2032)
  9. 10.5 China Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Sepsis and Septic Shock Treatment Revenue (2021-2032)
  2. 11.2 Asia Sepsis and Septic Shock Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Sepsis and Septic Shock Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Sepsis and Septic Shock Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Sepsis and Septic Shock Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Sepsis and Septic Shock Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Sepsis and Septic Shock Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Sepsis and Septic Shock Treatment Revenue by Country
  11. 11.6.1 Asia Sepsis and Septic Shock Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Sepsis and Septic Shock Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Sepsis and Septic Shock Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Sepsis and Septic Shock Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Sepsis and Septic Shock Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Sepsis and Septic Shock Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Sepsis and Septic Shock Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Sepsis and Septic Shock Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Sepsis and Septic Shock Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Sepsis and Septic Shock Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Sepsis and Septic Shock Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Sepsis and Septic Shock Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Sepsis and Septic Shock Treatment Revenue by Country
  11. 12.6.1 SAMEA Sepsis and Septic Shock Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Sepsis and Septic Shock Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Sepsis and Septic Shock Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst